Theriva Biologics
TOVX
11 hedge funds and large institutions have $210K invested in Theriva Biologics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
248% more capital invested
Capital invested by funds: $60.3K → $210K (+$149K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
5.62% more ownership
Funds ownership: 1.24% → 6.86% (+5.6%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$168K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$49.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$29 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$13.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.44K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$573 |
| 5 |
IHWM
Iron Horse Wealth Management
Johston,
Iowa
|
-$25 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| $132K | +$168K | +120,031 | New |
|
|
BFM
2
Boothbay Fund Management
New York
| $39.2K | +$49.8K | +35,601 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $20.6K | +$26.1K | +18,683 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $8.64K | -$12K | -8,555 | -52% |
|
5
BlackRock
New York
| $8.32K | – | – | – |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $972 | -$573 | -410 | -32% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $45 | +$29 | +21 | +105% |
|
|
IA
8
IFP Advisors
Tampa,
Florida
| $12 | – | – | – |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $11 | – | – | – |
|
|
PW
10
Pandora Wealth
Oakbrook Terrace,
Illinois
| $4 | +$6 | +4 | New |
|
|
DB
11
Danske Bank
Copenhagen K,
Denmark
| $1 | – | – | – |
|
|
12
Citigroup
New York
| – | -$13.6K | -7,756 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$2.44K | -1,391 | Closed |
|
|
IHWM
14
Iron Horse Wealth Management
Johston,
Iowa
| – | -$25 | -14 | Closed |
|
TOVX Hedge Fund Activity: Q1 2025 in Review
11 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2025, worth a combined $210K — up 248% from $60.3K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TOVX positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $168K. The largest seller was Citigroup, exiting entirely with an estimated $13.6K sold.
- 11 institutional investors held Theriva Biologics (TOVX) as of Q1 2025, up from 10 in Q4 2024.
- Funds reported $210K of Theriva Biologics stock for Q1 2025, up 248% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q1 2025 and 3 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q1 2025 was Ikarian Capital, an estimated $168K added.
- The largest Theriva Biologics seller in Q1 2025 was Citigroup, an estimated $13.6K sold.
Based on aggregated 13F filings for Q1 2025.